SCHEMBL4712967

SCHEMBL4712967

N/C(=C\[C]=O)Cc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 2/20 0.45
CES2 O00748 1/20 0.45
AKR1B1 P15121 1/20 0.45
HIF1A Q16665 1/20 0.42
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
FNTA P49354 1/20 0.38
FNTB P49356 1/20 0.38
L3MBTL1 Q9Y468 3/20 0.37
MAPK1 P28482 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
HTT P42858 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
ALDH1A1 P00352 3/20 0.37
CTBP2 P56545 1/20 0.37
EPHX2 P34913 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5184996 0.78 CES1 (0.55) CES1CES2AKR1B1HIF1AKMT2A
SCHEMBL28079137 0.76 CES1 (0.45) CES1CES2AKR1B1KMT2AMEN1
SCHEMBL31568852 0.74 CTSL (0.47) CES1CES2AKR1B1HIF1AKMT2A
SCHEMBL18768682 0.74 CES2 (0.46) CES1CES2AKR1B1HIF1AKMT2A
SCHEMBL3473792 0.74 CES1 (0.46) CES1CES2AKR1B1HIF1AKMT2A
SCHEMBL3917563 0.73 CES1 (0.52) CES1CES2AKR1B1HIF1AKMT2A
SCHEMBL4712969 0.73 AKR1B1 (0.52) CES1CES2AKR1B1HIF1AKMT2A
SCHEMBL3917561 0.73 CES1 (0.52) CES1CES2AKR1B1HIF1AKMT2A
SCHEMBL3675795 0.72 CES1 (0.50) CES1CES2AKR1B1HIF1AKMT2A
Hydrochloric Acid SCHEMBL4304721 0.72 CES2 (0.44) CES1CES2AKR1B1HIF1AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7402595-B2 Enzyme inhibitors with isoquinolinone structures TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-22 US disclosed
US-20050148624-A1 Jnk inhibitor TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-07-07 US disclosed
EP-1484320-A1 JNK INHIBITOR Takeda Chemical Industries, Ltd. (JP) 2004-12-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148624-A1 Jnk inhibitor MAPK3, MAPKAPK3, MAPK1 CES1 2078/4885CES2 2833/4885AKR1B1 2083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.